Background
The Department of Veterans Affairs solicited a national requirements contract for hydroxychloroquine tablets, used to treat chronic rheumatoid arthritis. The solicitation contemplated award to the lowest-priced, technically acceptable offeror and required products to qualify as either U.S.-made or designated-country end products under the Trade Agreements Act. AvKare offered domestically manufactured tablets, while Bryant Ranch Prepack Pharmaceuticals offered lower-priced tablets made with an active pharmaceutical ingredient synthesized in Taiwan and processed into tablet form in India.
The VA selected Bryant Ranch after determining that its tablets complied with the TAA. Following AvKare’s protest in the Court of Federal Claims, the agency obtained additional manufacturing evidence during a voluntary remand and reaffirmed the award. AvKare then argued that the tablets were products of India, a non-designated country, and that Bryant Ranch was therefore technically unacceptable.
The Court’s Holding
The court held that the VA reasonably determined that the tablets’ last substantial transformation occurred in Taiwan, a TAA-designated country. The record supported the agency’s finding that multistep chemical synthesis in Taiwan created the hydroxychloroquine sulfate active ingredient and imparted its molecular structure, pharmacological activity, and predetermined therapeutic use. The subsequent operations in India were routine dosage-form processes that did not alter the ingredient’s chemical identity or therapeutic function.
The court also found that the VA independently assessed the country of origin rather than merely accepting Bryant Ranch’s certification or treating Customs and Border Protection rulings as binding. The agency sought detailed evidence, reviewed the manufacturing processes, applied the statutory name-character-use test, and used CBP decisions only as persuasive support. Under the deferential Administrative Procedure Act standard, that analysis was rational and supported by substantial evidence.
Because Bryant Ranch offered the lowest-priced, technically acceptable proposal, the award complied with the solicitation and the TAA. The court denied AvKare’s motion for judgment on the administrative record and granted the government’s and Bryant Ranch’s cross-motions.
Key Takeaways
- For a designated-country end product, the TAA inquiry turns on where the product was last substantially transformed, not automatically on where its final dosage form was produced.
- The VA reasonably found that synthesis of the active pharmaceutical ingredient in Taiwan supplied the drug’s essential identity and use, while tableting in India did not create another substantial transformation.
- A contracting agency must make its own country-of-origin determination, although it may consult CBP decisions as persuasive authority.
Why It Matters
The decision illustrates how contracting agencies may evaluate TAA compliance in multinational pharmaceutical supply chains. Final formulation or tableting in a non-designated country does not necessarily establish that country as the product’s origin when the active ingredient already possesses its essential chemical character and predetermined therapeutic use.
The ruling also underscores the limits of bid-protest review. The court did not decide that the agency was compelled to reach only one possible conclusion; it held that the VA considered the relevant evidence, applied the correct legal framework, and reached a conclusion within the bounds of rational decision-making.